iRhythm Technologies, Inc.(IRTC)Earnings, Financials & Key RatiosiRhythm Technologies, Inc. (IRTC) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
while the company maintains a healthy current ratio of 5.17, the persistent inability to generate consistent free cash flow and the high debt-to-equity ratio of 4.52 warrant a wait-and-see approach until operational leverage is clearly established.
iRhythm Technologies, Inc. (IRTC) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
iRhythm Technologies, Inc. (IRTC) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 30, 2026 | $0.35vs $0.56+37.5% | $199Mvs $194M+2.7% |
| Q1 2026 | Feb 19, 2026 | $0.17vs $0.02+750.0% | $209Mvs $202M+3.5% |
| Q4 2025 | Oct 30, 2025 | $0.06vs $0.36+83.3% | $193Mvs $202M-4.4% |
| Q3 2025 | Jul 31, 2025 | $0.32vs $0.53+39.6% | $187Mvs $176M+6.4% |
Recent stock market news and headlines for iRhythm Technologies, Inc. (IRTC)
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
NEW YORK, July 2, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of iRhythm Technologies, Inc. (NASDAQ: IRTC) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Insiders at iRhythm caused the company to misrepresent or fail to disclose that the Zio AT monitor was a real-time monitor intended for high-risk patients.
NEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of iRhythm Technologies, Inc. (NASDAQ: IRTC) breached their fiduciary duties to shareholders.
iRhythm Holdings on Monday reported unauthorized activity involving data maintained on some third-party applications last week, but said it has not identified any impact on products, patient safety or medical device systems from the cyber attack.
Key metrics vs top competitors for iRhythm Technologies, Inc. (IRTC)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $125.09 | $4.11B | -89.99 | 26.24% | -5.96% | -36.57% | — | |
| $91.90 | $3.16B | 31.80 | 7.57% | 7.67% | 8.23% | — | |
| $22.25 | $1.64B | 6.74 | 18.52% | 118.91% | 47.59% | — | |
| $156.30 | $56.63B | 26.81 | 8.23% | 5.33% | 4.54% | — | |
| $76.01 | $16.97B | 30.53 | 1.74% | 13.18% | 11.01% | — | |
| $17.72 | $2.02B | -14.52 | 8.28% | -25.66% | -50.82% | — |
iRhythm Technologies, Inc. (IRTC) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
iRhythm Technologies, Inc. (IRTC) SEC filings — annual & quarterly reports (10-K, 10-Q)
Apr 30, 2026·SEC
Apr 1, 2026·SEC
Mar 12, 2026·SEC
Get notified when IRTC posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
iRhythm Technologies, Inc. (IRTC) stock FAQ — growth, dividends, profitability & financials explained
iRhythm Technologies, Inc. (IRTC) reported $787.9M in revenue for fiscal year 2025. This represents a 5027% increase from $15.4M in 2013.
iRhythm Technologies, Inc. (IRTC) grew revenue by 26.2% over the past year. This is strong growth.
iRhythm Technologies, Inc. (IRTC) reported a net loss of $27.8M for fiscal year 2025.
iRhythm Technologies, Inc. (IRTC) has a return on equity (ROE) of -36.6%. Negative ROE indicates the company is unprofitable.
iRhythm Technologies, Inc. (IRTC) generated $18.8M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
